RARE - Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

2024-03-09 09:55:42 ET

Summary

• Ultragenyx's stock has increased by approximately 9% but lags behind the S&P's return of 28%.
• The article assesses Ultragenyx's current merits per its recently reported Q4, 2023 earnings as we progress into 2024.
• The previous "Sell" rating based on a downward trajectory and lack of catalysts may need to be reevaluated.

This is my second Ultragenyx ( RARE ) article, following 09/2022's "Downward Trajectory Likely To Continue" (" Trajectory "). In Trajectory, I acknowledged its several manifest attractions; nonetheless, I rated it as a "Sell" based upon its downward share price movement and its lack of near turn catalysts to reverse the trajectory....

For further details see: